Keros Therapeutics, Inc. business relationships
Companies named in Keros Therapeutics, Inc.’s 10-K filed 2026-03-04, and public companies whose annual reports name Keros Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 3.5 / 10
- AI naming
- <1 / 100 Top 55% in its category
- Agent readiness
- 30 / 100
- AI adoption
- 0 / 100
Named in Keros Therapeutics, Inc.’s annual report 2
“2024 License Agreement with Takeda Pharmaceuticals U.S.A., Inc.” SEC filing
“activities under our collaboration with Takeda.” SEC filing
Companies whose annual reports name Keros Therapeutics, Inc. 2
“In December 2024, Takeda entered into an exclusive licensing agreement with Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.” SEC filing
“*5 Partnership with Keros Therapeutics, Inc.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.